Dendreon Corporation (Nasdaq: DNDN) today reported regulatory and commercialization progress for PROVENGE® (sipuleucel-T), the company’s investigational prostate cancer product. Dendreon expects to prepare for commercialization of PROVENGE by the middle of next year. Dendreon further plans to initiate a clinical trial of NEUVENGE™ (lapuleucel-T) to treat bladder cancer, and potentially, breast and colorectal cancers. At today’s analyst event, the company also reported the expansion of its manufacturing facility in New Jersey and the addition of facilities in Los Angeles and Atlanta, as well as a significant expected increase in staffing in preparation for the product launch next year.
Mitchell Gold – Dendreon’s CEO – will be a panelist at the BIO Investor Forum’s Prostate Cancer Therapeutic Workshop.